Volume 21, Issue 9 (12-2022)
JRUMS 2022, 21(9): 955-970 |
Back to browse issues page
Ethics code: IR.KMU.REC.1398.082
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shojaei M, Rokhbakhsh-Zamin F, Rezazadeh Zarandi E, Sarafzadeh F, Khoshroo S M R. The Frequency of Antibiotic Resistance of Clinical Isolates of Clostridioides difficile to Commonly Used Antibiotics in Hospitalized Patients of Educational Hospitals of Kerman City During 2018-2020. JRUMS 2022; 21 (9) :955-970
URL: http://journal.rums.ac.ir/article-1-6756-en.html
URL: http://journal.rums.ac.ir/article-1-6756-en.html
MohammadSaeed Shojaei 
, Farokh Rokhbakhsh-Zamin , Ebrahim Rezazadeh Zarandi , Farhad Sarafzadeh , Sayed Mohammad Reza Khoshroo
, Farokh Rokhbakhsh-Zamin , Ebrahim Rezazadeh Zarandi , Farhad Sarafzadeh , Sayed Mohammad Reza Khoshroo
Islamic Azad University Kerman Branch
Full-Text [PDF 306 kb]
(424 Downloads)
| Abstract (HTML) (797 Views)
Full-Text: (462 Views)
The Frequency of Antibiotic Resistance of Clinical Isolates of Clostridioides difficile to Commonly Used Antibiotics in Hospitalized Patients of Educational Hospitals of Kerman City During 2018-2020
MohammadSaeed Shojaei[1], Farokh Rokhbakhsh-Zamin[2], Ebrahim Rezazadeh Zarandi[3], Farhad Sarafzadeh[4], Sayed Mohammad Reza Khoshroo[5]
Received: 18/09/22 Sent for Revision: 23/10/22 Received Revised Manuscript: 13/12/22 Accepted: 14/12/22
Background and Objectives: Clostridioides difficile (C. difficile) is one of the main causes of antibiotic-associated diarrhea. It is important to find out the pattern of its antimicrobial susceptibility for reducing prevalence and also treating C. difficile infection (CDI). This study aims to investigate the antimicrobial resistance of C. difficile to commonly used antibiotics, especially vancomycin and metronidazole, as the most effective antibiotics against the bacterium.
Materials and Methods: In this descriptive study, 417 diarrheal stool samples were taken from hospitalized patients of educational hospitals of Kerman City from 2018 to 2020. The samples were cultured on cycloserine-cefoxitin fructose agar (CCFA), and suspected C. difficile colonies were isolated. Identification of the cdd-3 gene for definitive diagnosis of C. difficile was performed. Antibiotic resistance test was conducted by the disk-diffusion method using vancomycin, metronidazole, rifampin, amoxicillin-clavulanic acid, erythromycin, imipenem, ciprofloxacin, and clindamycin disks. The results were reported as numbers and percentages.
Results: A total of 68 (16.3%) isolates of C. difficile were taken from the samples. Most C. difficile strains were susceptible to vancomycin and metronidazole, while the highest rate of resistance was related to ciprofloxacin and clindamycin. The prevalence of multi-drug resistant (MDR) strains was 77.9%.
Conclusion: The results of this study showed that vancomycin is still the best antibiotic for treating CDI. Also, the frequency of the isolates resistant to CDI-inducing antibiotics (erythromycin, clindamycin, ciprofloxacin) and MDR isolates was high. Therefore, the spread of resistant strains of C. difficile can be prevented by appropriate antibiotic prescription.
Key words: Clostridioides difficile, Antibiotic resistance, Multi-drug resistant (MDR), Kerman
Funding: This study did not have any funds.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Kerman University of Medical Sciences approved this study (IR.KMU.REC.1398.082).
How to cite this article: Shojaei MohammadSaeed, Rokhbakhsh-Zamin Farokh, Rezazadeh Zarandi Ebrahim, Sarafzadeh Farhad, Khoshroo Sayed Mohammad Reza. The Frequency of Antibiotic Resistance of Clinical Isolates of Clostridioides difficile to Commonly Used Antibiotics in Hospitalized Patients of Educational Hospitals of Kerman City During 2018-2020. J Rafsanjan Univ Med Sci 2022; 21 (9): 955-70. [Farsi]
MohammadSaeed Shojaei[1], Farokh Rokhbakhsh-Zamin[2], Ebrahim Rezazadeh Zarandi[3], Farhad Sarafzadeh[4], Sayed Mohammad Reza Khoshroo[5]
Received: 18/09/22 Sent for Revision: 23/10/22 Received Revised Manuscript: 13/12/22 Accepted: 14/12/22
Background and Objectives: Clostridioides difficile (C. difficile) is one of the main causes of antibiotic-associated diarrhea. It is important to find out the pattern of its antimicrobial susceptibility for reducing prevalence and also treating C. difficile infection (CDI). This study aims to investigate the antimicrobial resistance of C. difficile to commonly used antibiotics, especially vancomycin and metronidazole, as the most effective antibiotics against the bacterium.
Materials and Methods: In this descriptive study, 417 diarrheal stool samples were taken from hospitalized patients of educational hospitals of Kerman City from 2018 to 2020. The samples were cultured on cycloserine-cefoxitin fructose agar (CCFA), and suspected C. difficile colonies were isolated. Identification of the cdd-3 gene for definitive diagnosis of C. difficile was performed. Antibiotic resistance test was conducted by the disk-diffusion method using vancomycin, metronidazole, rifampin, amoxicillin-clavulanic acid, erythromycin, imipenem, ciprofloxacin, and clindamycin disks. The results were reported as numbers and percentages.
Results: A total of 68 (16.3%) isolates of C. difficile were taken from the samples. Most C. difficile strains were susceptible to vancomycin and metronidazole, while the highest rate of resistance was related to ciprofloxacin and clindamycin. The prevalence of multi-drug resistant (MDR) strains was 77.9%.
Conclusion: The results of this study showed that vancomycin is still the best antibiotic for treating CDI. Also, the frequency of the isolates resistant to CDI-inducing antibiotics (erythromycin, clindamycin, ciprofloxacin) and MDR isolates was high. Therefore, the spread of resistant strains of C. difficile can be prevented by appropriate antibiotic prescription.
Key words: Clostridioides difficile, Antibiotic resistance, Multi-drug resistant (MDR), Kerman
Funding: This study did not have any funds.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Kerman University of Medical Sciences approved this study (IR.KMU.REC.1398.082).
How to cite this article: Shojaei MohammadSaeed, Rokhbakhsh-Zamin Farokh, Rezazadeh Zarandi Ebrahim, Sarafzadeh Farhad, Khoshroo Sayed Mohammad Reza. The Frequency of Antibiotic Resistance of Clinical Isolates of Clostridioides difficile to Commonly Used Antibiotics in Hospitalized Patients of Educational Hospitals of Kerman City During 2018-2020. J Rafsanjan Univ Med Sci 2022; 21 (9): 955-70. [Farsi]
[1]- PhD Student, Dept. of Microbiology, Faculty of Sciencs, Kerman Branch, Islamic Azad University, Kerman, Iran
[2]- Assistant Prof., Dept. of Microbiology, Faculty of Sciencs, Kerman Branch, Islamic Azad University, Kerman, Iran, ORCID: 0000-0001-8151-553X
(Corresponding Author) Tel: (034) 31321343, Fax: (034) 31321343, E-mail: rokhbakhsh@gmail.com
(Corresponding Author) Tel: (034) 31321343, Fax: (034) 31321343, E-mail: rokhbakhsh@gmail.com
[3]- Assistant Professor, Immunology of Infection of Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran, ORCIDE: 0000-0001-7067-2214
(Corresponding Author) Tel: (034) 31315000, Fax: (034) 31315000, E-mail: erezazadehzarandi50@gmail.com
[4]- Associate Prof., Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
[4]- Associate Prof., Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
[5]- Assistant Prof., Dept. of Microbiology, Faculty of Sciencs, Kerman Branch, Islamic Azad University, Kerman, Iran
Type of Study: Research |
Subject:
Microbiology
Received: 2022/11/7 | Accepted: 2022/12/24 | Published: 2022/12/19
Received: 2022/11/7 | Accepted: 2022/12/24 | Published: 2022/12/19
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
